Description
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Catalog No.
DVV03801
Host species
Homo sapiens
Species reactivity
Influenza A virus
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.76 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, lambda
Applications
Research Grade Biosimilar
Target
HA/Hemagglutinin
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03455
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字： Diridavumab;HA/Hemagglutinin;
武汉佰乐博生物（Biolab Reagents）始创于 2021 年，核心创始团队由五位毕业于武汉大学、华中科技大学、华中农业大学等知名高校的生命科学领域顶尖研究者组成。团队成员均深耕行业二十载，积淀了深厚的产品开发实力与成熟的技术应用经验，为企业发展筑牢核心技术根基。
佰乐博生物是国家高新技术企业、国家科技型中小企业，技术实力获权威认可；同时通过 ISO9001 质量管理体系、ISO13485 医疗器械质量管理体系双认证，以标准化、规范化的品控体系，筑牢产品品质基石。公司依托全球领先的技术平台，专注于高品质生物试剂的全球化开发与整合，与法国 AntibodySystem 品牌达成深度战略合作，系其在亚洲的独家授权合作伙伴以及生工生物KleanAB品牌的代理商。目前已构建起近 60000 种生命科学试剂的丰富产品矩阵，核心产品涵盖蛋白、抗体、试剂盒三大品类，重点覆盖肿瘤、神经系统等疾病研究热门领域，可全维度满足各类科研实验的多元需求。
自成立以来，佰乐博生物始终秉持初心，致力于为广大生命科学科研工作者、生物医药工业客户提供专业、全面、可靠的试剂产品与技术支持，以优质科研工具赋能科研探索，助力生命科学研究领域实现创新发展与深度突破。